Loading…
Neurocrine Biosciences, Inc. is projected to rise to $245.52 by 2027, a +32% move from its current price of $185.50. NBIX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $182.50 | $185.50 | $188.55 | 0.00% |
| Aug 2 | $181.27 | $185.50 | $189.83 | 0.00% |
| Aug 3 | $180.34 | $185.51 | $190.82 | 0.00% |
| Aug 4 | $179.55 | $185.51 | $191.66 | 0.00% |
| Aug 5 | $178.87 | $185.51 | $192.40 | +0.01% |
| Aug 6 | $178.25 | $185.51 | $193.08 | +0.01% |
| Aug 7 | $177.68 | $185.51 | $193.70 | +0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $177.68 | $185.51 | $193.70 | +0.01% |
| Week 2 | $174.54 | $185.53 | $197.21 | +0.02% |
| Week 3 | $172.18 | $185.54 | $199.95 | +0.02% |
| Week 4 | $170.21 | $185.56 | $202.29 | +0.03% |
| Week 5 | $168.50 | $185.57 | $204.38 | +0.04% |
| Week 6 | $166.97 | $185.59 | $206.29 | +0.05% |
| Week 7 | $165.57 | $185.60 | $208.06 | +0.06% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Neurocrine Biosciences, Inc. is a healthcare company that discovers, develops, and commercializes pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. Its product portfolio includes INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as products under the names ALKINDI and Efmody.
The company was incorporated in 1992 and is headquartered in San Diego, California. It also maintains license and collaboration agreements with multiple pharmaceutical partners, reflecting its collaborative development approach across its clinical and commercial activities.
Neurocrine Biosciences, Inc. (NBIX) is a healthcare company with a focus on pharmaceuticals. It is currently priced at $182.83 per share, with a market capitalization of $18.38B and a rank of 606.
The price outlook is bullish over the longer horizon, with the forecast showing rising averages from $182.83 in 2026 to $419.62 in 2030 and up to $2,647.99 by 2050, with max values reaching $4,328.47. The sequence of annual ROIs ranges from 0% in 2026 to as high as 1,348.3% by 2050, indicating substantial upside potential according to the forecast.
A major floor 31.9% below — a decisive break under it would weaken the trend.
The nearest floor, 14.7% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 9.8% above — clearing it would confirm fresh momentum.
Key NBIX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NBIX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $180.26 | Buy | $181.02 | Buy |
| MA 10 | $177.11 | Buy | $178.46 | Buy |
| MA 20 | $176.13 | Buy | $175.32 | Buy |
| MA 50 | $167.11 | Buy | $166.91 | Buy |
| MA 100 | $150.92 | Buy | $157.38 | Buy |
| MA 200 | $145.76 | Buy | $148.46 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 67.09 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 190.38 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.46 | Buy |
| ROC (12) | 7.82 | Buy |
| Bollinger %B (20,2) | 1.10 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.31 | Buy |
| Awesome (5,34) | 9.48 | Buy |
| Ultimate (7,14,28) | 63.80 | Neutral |
| Momentum (10) | 13.95 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 183.80 | Buy |
| ADX (14) | 23.49 | Buy |
| ATR (14) | 2.75 | Info |
The 30-day technical picture is bullish, with an RSI of 60 and a current sentiment labeled as BULLISH. The 30-day range is $164.83 to $202.80, and the stock trades above the 50-day simple moving average of $165.33 and above the 200-day simple moving average of $144.90.
Support is at $156.42 and resistance at $180.55, providing a defined near-term trading framework. Annualized volatility is about 30%, reflecting notable but manageable price dispersion in the market over a year.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $123.10 | $185.50 | $231.65 | 0% | Neutral | |
| $201.31 | $245.52 | $312.91 | +32% | Bullish | |
| $249.53 | $310.12 | $406.09 | +67% | Bullish | |
| $308.26 | $389.08 | $520.44 | +110% | Bullish | |
| $355.76 | $455.13 | $619.85 | +145% | Bullish | |
| $395.67 | $512.40 | $708.94 | +176% | Bullish | |
| $441.71 | $578.51 | $811.86 | +212% | Bullish | |
| $483.75 | $640.27 | $910.22 | +245% | Bullish | |
| $592.66 | $792.24 | $1,139.77 | +327% | Bullish | |
| $707.50 | $954.73 | $1,388.89 | +415% | Bullish | |
| $1,113.12 | $1,566.79 | $2,388.89 | +745% | Bullish | |
| $2,116.17 | $3,194.81 | $5,222.15 | +16.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $123.10 | $185.50 | $215.95 | +0.00% |
| August 2026 | $157.16 | $183.25 | $217.76 | -1.21% |
| September 2026 | $158.34 | $185.69 | $222.73 | +1.33% |
| October 2026 | $161.57 | $190.35 | $230.02 | +2.51% |
| November 2026 | $160.19 | $189.43 | $230.28 | -0.48% |
| December 2026 | $159.72 | $189.52 | $231.65 | +0.05% |
Click any year to see its month-by-month NBIX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, NBIX is projected to trade between $123.10 and $231.65, averaging $185.50 — a potential gain of 0% from today's $185.50. Price action looks broadly range-bound.
Neurocrine Biosciences, Inc.'s 2027 outlook centres on $245.52, within a $201.31 to $312.91 range. That is up +32% on the projected 2026 average. That marks a +32% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, NBIX could reach as high as $406.09, with a base case around $310.12 and support toward $249.53 — roughly +67% from $185.50. Momentum favours further upside here.
Expect NBIX to range from $308.26 to $520.44 through 2029. The $389.08 average target implies a +110% move from current prices. That is up +25% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The NBIX price prediction for 2030 points to an average of $455.13 (low $355.76, high $619.85) — a potential gain of +145% on today's $185.50. Momentum favours further upside here.
In 2031, NBIX is projected to trade between $395.67 and $708.94, averaging $512.40 — a potential gain of +176% from today's $185.50. That is up +13% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Neurocrine Biosciences, Inc.'s 2032 outlook centres on $578.51, within a $441.71 to $811.86 range. That is up +13% on the projected 2031 average. That marks a +212% change versus current levels. Momentum favours further upside here.
By 2033, NBIX could reach as high as $910.22, with a base case around $640.27 and support toward $483.75 — roughly +245% from $185.50. Buyers look set to stay in control over this stretch.
Expect NBIX to range from $592.66 to $1,139.77 through 2034. The $792.24 average target implies a +327% move from current prices. That is up +24% on the projected 2033 average. Momentum favours further upside here.
The NBIX price prediction for 2035 points to an average of $954.73 (low $707.50, high $1,388.89) — a potential gain of +415% on today's $185.50. Buyers look set to stay in control over this stretch.
In 2040, NBIX is projected to trade between $1,113.12 and $2,388.89, averaging $1,566.79 — a potential gain of +745% from today's $185.50. That is up +64% on the projected 2035 average. Momentum favours further upside here.
Neurocrine Biosciences, Inc.'s 2050 outlook centres on $3,194.81, within a $2,116.17 to $5,222.15 range. That is up +104% on the projected 2040 average. That marks a +16.2x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in NBIX today (≈ 5.390836 NBIX) could be worth
$17,222.71
+$16,222.71 (+1622%) by 2050 · US Dollar
Based on the average projected NBIX price of $3,194.81 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NBIXwould be worth at today's price.
$1,000 invested in NBIX on Jul 30, 2025 (≈ 7.31208 NBIX) would be worth
$1,356.39
+$356.39 (+35.6%) today · 1.36× · US Dollar
Based on a NBIX entry price of $136.76 vs. today's $185.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $174.15 | $1,065.17 | +6.5% |
| 1 month ago | $168.54 | $1,100.63 | +10.1% |
| 3 months ago | $131.78 | $1,407.65 | +40.8% |
| 6 months ago | $136.06 | $1,363.37 | +36.3% |
| 1 year ago | $136.76 | $1,356.39 | +35.6% |
| All time (5.0y) ago | $95.91 | $1,934.1 | +93.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NBIX forecast.
Our base-case forecast reaches $370.00 around 2029.
Implied market cap at $370.00: $37.2B
The multi-year forecast shows substantial upside. In 2026, the avg is $182.83 with min $123.10 and max $226.85, ROI 0%, sentiment NEUTRAL. From 2027 onward, the forecast is bullish, with 2027 avg $235.76 and max $300.51 (min $193.28), ROI 28.9%.
By 2028, avg $291.20, max $381.37 (min $234.28), ROI 59.3%. In 2029, avg $362.20, max $484.54 (min $286.94), ROI 98.1%. By 2030, avg $419.62, max $571.54 (min $327.98), ROI 129.5%.
The bullish trajectory continues through 2031–2035, with 2031 avg $465.43, 2032 $520.52, 2033 $569.38, 2034 $694.57, and 2035 $835.79. Rider years show continuing upside: 2040 avg $1,322.84 (min $939.77, max $2,017.03; ROI 623.5%), and 2050 avg $2,647.99 (min $1,753.90, max $4,328.47; ROI 1348.3%). Overall, the outlook runs bullish across the extended horizon, but these are estimates and not guaranteed.
Drivers and risks are not enumerated in the figures, so investors should consider these projections as indicative rather than certain.
Tap a question to reveal the answer.
Avg $419.62, min $327.98, max $571.54, ROI 129.5%, sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising averages; 2026 is neutral. These are estimates and not guaranteed, so results depend on future developments.
Yes. The forecast shows a 2040 max of $2,017.03 and a 2050 max of $4,328.47, with 2050 avg $2,647.99, indicating the potential to exceed $1,000 in the longer term.
Current price $182.83; Market cap $18.38B.
The 30-day range is $164.83-$202.80; RSI 60; SMA50 $165.33; SMA200 $144.90; support $156.42; resistance $180.55; annualized volatility 30%.
Neurocrine Biosciences, Inc. Community Discussion
0Share your Neurocrine Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.